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org/licenses/by-nc-nd/4.0/).Abstract Background and aims: Plant sterols (PS) lower plasma LDL-cholesterol through partial
inhibition of intestinal cholesterol absorption. Although PS themselves are poorly absorbed,
increased intakes of PS result in elevated plasma concentrations. In this paper, we report time
curves of changes in plasma PS during 12 weeks of PS intake. Furthermore, the impact of choles-
terol synthesis and absorption on changes in plasma PS is explored.
Methods and results: The study was a double-blind, randomized, placebo-controlled, parallel-
group study with the main aim to investigate the effects of PS on vascular function
(clinicaltrials.gov: NCT01803178). Hypercholesterolemic but otherwise healthy men and women
(n Z 240) consumed low-fat spreads without or with added PS (3 g/d) for 12 weeks after a 4-
week run-in period. Blood sampling was performed at week 0, 4, 8 and 12. Basal cholesterol-
standardized concentrations of lathosterol and sitosterol þ campesterol were used as markers
of cholesterol synthesis and absorption, respectively. In the PS group, plasma sitosterol and cam-
pesterol concentrations increased within the ﬁrst 4 weeks of intervention by 69% (95%CI: 58; 82)
starting at 7.2 mmol/L and by 28% (95%CI: 19; 39) starting at 11.4 mmol/L, respectively, and re-
mained stable during the following 8 weeks. Placebo-corrected increases in plasma PS were
not signiﬁcantly different between high and low cholesterol synthesizers (P-values >0.05). Be-
tween high and low cholesterol absorbers, no signiﬁcant differences were observed, except for
the cholesterol-standardized sum of four major plasma PS (sitosterol, campesterol, brassicasterol
and stigmasterol) showing larger increases in low absorbers (78.3% (95%CI: 51.7; 109.5))
compared to high absorbers (40.8% (95%CI: 19.9; 65.5)).
Conclusions: Increases in plasma PS stabilize within 4 weeks of PS intake and do not seem
impacted by basal cholesterol synthesis or absorption efﬁciency.
This study was registered at clinicaltrials.gov (NCT01803178).
ª 2015 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., Unilever R&D Vlaardingen, Olivier van Noortlaan 120, P.O. Box 114, 3130 AC Vlaardingen, The Netherlands.
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Plant sterols (PS) are lipid-like compounds that occur natu-
rally in small amounts in plant-based foods and in higher
amounts in speciﬁc enriched foods. Consumption of foods
with added PS is effective in lowering total-, and especially,
LDL-cholesterol concentrations [1,2]. LDL-cholesterol is the
most important blood lipid risk factor for coronary heart
disease (CHD) [3,4].
PS inhibit intestinal cholesterol absorption [5] through
several hypothesized mechanisms such as competition
with cholesterol for solubilization in dietary mixed mi-
celles, interference with transport-mediated processes of
cholesterol uptake and stimulation of cholesterol excre-
tion via the intestine [6,7]. The inhibition of intestinal
cholesterol absorption with PS intake occurs rapidly and
the maximal LDL-cholesterol lowering effect for a given
dose of PS is usually achieved within the ﬁrst 2e3 weeks
of intake. PS in contrast to cholesterol are poorly absor-
bed from the intestine. In fact, due to active excretion of
PS by the ABCG5/G88 transporters from the enterocytes
back into the intestinal lumen and from the liver into the
bile, net absorption of PS is less than 5% [8]. Consequently,
circulating PS concentrations in humans are relatively
low, i.e. w250 times lower compared to cholesterol [9].
Nevertheless, when intakes of PS are high, e.g. with
intake of foods with added PS, plasma PS concentrations
modestly increase [10]. It is not well established how
rapidly plasma PS concentrations rise, and whether the
increase in plasma PS will stabilize over time. Addition-
ally, some earlier studies have suggested that part of the
variation in the LDL-cholesterol-lowering efﬁcacy of PS is
explained by endogenous factors of cholesterol meta-
bolism such as cholesterol synthesis and/or absorption
efﬁciency [11]. Whether cholesterol metabolism would
also explain some of the variation in increases in plasma
PS after PS-enriched food intake requires further
investigation.
The primary result of this large randomized interven-
tion study provided evidence that the regular intake of a
low-fat spread with added PS (3 g/d) lowered total- and
LDL-cholesterol whereas endothelial function as measured
by ﬂow-mediated dilation (FMD) was neither improved
nor worsened [12]. No correlation was observed between
changes in plasma PS and changes in FMD whereas a
modest but signiﬁcant correlation was observed between
changes in LDL-cholesterol and changes in FMD [12]. In the
current paper, we aimed to investigate the changes over
time in plasma sitosterol and campesterol concentrations
during 12 weeks of PS intake. In addition, the PS-induced
changes over time in total- and LDL-cholesterol were
investigated. Furthermore, we explored the impact of
cholesterol metabolism, more speciﬁcally of cholesterol
synthesis and absorption efﬁciency as determined by basal
non-cholesterol sterols standardized for total cholesterol
(TC), on the changes in plasma PS and serum lipids after PS
intake.Methods
Study population
Hypercholesterolemic, but otherwise healthy, men and
post-menopausal women were recruited among in-
habitants of Berlin and surroundings through advertise-
ments. Individuals were selected based on the following
main selection criteria: being apparently healthy; aged
between 40 and 65 y; having LDL-cholesterol between 3.4
and 4.9 mmol/L; having a BMI between 18 and 30 kg/m2;
no occurrence of cardiovascular or systemic inﬂammatory
diseases or diabetes mellitus; no use of lipid-lowering
foods or drugs or other drugs that may interfere with
the study outcomes; not smoking; and willing to comply
with the study procedures. Informed consent was ob-
tained from all study participants. The protocol was
approved by the ethical committee of Charité Hospital
and was conducted in accordance with the Helsinki
declaration. This study was registered at clinicaltrials.gov
(NCT01803178).
Study design and measurements
This study was designed as a double-blind, randomized,
placebo-controlled, parallel-group intervention study.
Following a 4-week run-in period, study participants
were randomized, after stratiﬁcation for age, sex and
screening LDL-cholesterol, across two treatment groups:
20 g/d of low-fat (w40% fat) spread with added PS esters
(3 g/d, expressed in free PS equivalents) or 20 g/d of
placebo spread (comparable in fat composition, taste and
appearance). Participants consumed two 10 g portion
packs of spread daily. Consumption was recorded in a
diary and opened and unopened portion packs were
counted to determine compliance. The phytosterol
mixture contained 70% sitosterol, 14% campesterol, 8%
sitostanol, 3% brassicasterol, and some other phytosterols.
The intervention period lasted 12 weeks. The spreads
were produced by Unilever Research and Development
Vlaardingen, The Netherlands. Participants were instruc-
ted to consume their typical diet and minimize changes
in their diet and lifestyle habits, to refrain from foods
containing PS or other ingredients claiming to lower
blood cholesterol and to avoid using concomitant medi-
cation or vasoactive substances that could interfere with
the study outcomes. Full details of this study were
recently published [12].
Fasted blood samples were drawn at 4-week intervals
(week 0, 4, 8 and 12) for measuring serum lipids by
colorimetry on a Beckman Coulter AU analyzer (Synlab,
Germany) and plasma non-cholesterol sterols by gas
chromatography-mass spectrometry (GC-MS) with ﬂame
ionization detection (Unilever Research and Development
Vlaardingen [13]). All samples of each subject were
analyzed within the same assay. Lathosterol at baseline
was used as a marker of cholesterol synthesis whereas the
304 R.T. Ras et al.sum of plasma sitosterol and campesterol at baseline was
used as a marker of cholesterol absorption [14]. High or
low cholesterol synthesizers and high or low cholesterol
absorbers were deﬁned using, as cut-offs, the gender-
speciﬁc 25th and 75th percentiles of the basal lath-
osterol/TC ratio and the basal sitosterol þ campesterol/TC
ratio, respectively. Subjects with values between these
percentiles were excluded for this particular analysis. Non-
cholesterol to TC ratios were calculated using the choles-
terol concentration as derived from the same GC-MS assay.Statistics
Statistical analysis was performed using the JMP applica-
tion (version 11.0). Data of participants that violated the
protocol, as determined in a blind review process, were
excluded [12]. Both absolute and TC-standardized non-
cholesterol sterol concentrations and the sum of the four
major PS (sitosterol, campesterol, brassicasterol and stig-
masterol) were analyzed. Because most plasma non-
cholesterol sterols were not normally distributed, a log
transformation was applied for all non-cholesterol sterols,
after calculation of the ratios. Triglycerides were also log
transformed. Log transformation resulted in normally
distributed values appropriate for statistical analysis. AnTable 1 Subject characteristics.
All subjects
(nZ 240)
Cholesterol synth
Low
(n Z 59b)
Gender, f/m 90/150 22/37
Age, year 53.2  6.8 53.2  6.8
Weight, kg 77.7  13.0 73.1  12.5
BMI, kg/m2 25.3  2.8 23.8  2.8
Total cholesterol, mmol/L 5.75  0.94 5.84  0.88
LDL-cholesterol, mmol/L 3.90  0.63 3.93  0.63
HDL-cholesterol, mmol/L 1.38  0.43 1.52  0.41
Triglycerides, mmol/L 1.07 [0.77; 1.44] 0.91 [0.72; 1.18]
Sitosterol, mmol/L 6.36 [4.62; 7.92] 7.49 [6.45; 9.97]
Sitosterol/TCc, mmol/mmol 1.09 [0.83; 1.33] 1.29 [1.13; 1.61]
Campesterol, mmol/L 10.53 [7.82; 13.53] 12.48 [9.96; 17.27
Campesterol/TC, mmol/mmol 1.77 [1.38; 2.35] 2.13 [1.69; 2.88]
Brassicasterol, mmol/L 0.72 [0.48; 1.03] 0.89 [0.56; 1.18]
Brassicasterol/TC, mmol/mmol 0.13 [0.08; 0.19] 0.15 [0.09; 0.21]
Stigmasterol, mmol/L 0.39 [0.28; 0.60] 0.43 [0.32; 0.62]
Stigmasterol/TC, mmol/mmol 0.07 [0.05; 0.10] 0.08 [0.06; 0.11]
Plant sterols, mmol/L 17.92 [13.78; 22.46] 21.69 [18.18; 28.6
Plant sterols/TC, mmol/mmol 3.09 [2.40; 3.89] 3.85 [3.08; 4.76]
Lathosterol, mmol/L 7.14 [5.35; 8.99] 4.65 [4.05; 5.48]
Lathosterol/TC, mmol/mmol 1.23 [0.92; 1.56] 0.84 [0.65; 0.98]
Desmosterol, mmol/L 4.21 [3.38; 5.09] 3.53 [2.77; 3.86]
Desmosterol/TC, mmol/mmol 0.72 [0.59; 0.86] 0.60 [0.48; 0.69]
Sitostanol, mmol/L 1.37 [0.99; 1.78] 1.66 [1.40; 2.10]
Sitostanol/TC, mmol/mmol 0.23 [0.17; 0.30] 0.29 [0.24; 0.39]
Campestanol, mmol/L 0.55 [0.38; 0.85] 0.53 [0.39; 0.84]
Campestanol/TC, mmol/mmol 0.09 [0.07; 0.14] 0.10 [0.07; 0.14]
Values are expressed as mean  SD or, in case of not normally distribute
a High or low cholesterol synthesizers and high or low cholesterol absorb
percentiles of the basal lathosterol/TC ratio and the basal sitosterol þ cam
b This n is the maximal number of subjects that has been included to calc
missings may have been present.
c Non-cholesterol sterols were standardized by using the total cholesterANCOVA was performed with the change from baseline as
the outcome variable. For the time curves, we established
models based on repeated measurements including
treatment, baseline value, visit (week 4, 8 and 12) and a
treatment*visit interaction. For the cholesterol synthesis/
absorption analysis, we established models based on the
12-week data including treatment, baseline value, group
(high or low synthesizers/absorbers) and a treat-
ment*group interaction. For exploratory purposes, we
repeated the latter analysis for men and women sepa-
rately. A P-value <0.05 was considered statistically
signiﬁcant.Results
Subject characteristics
In total, 240 subjects (150 men and 90 women) were
enrolled into the study (Table 1). Eight subjects dropped out
prematurely. Six subjects violated the protocol (i.e. not
being weight stable) and were excluded from further anal-
ysis leaving maximally 226 subjects for the analysis. The
number of missing values in the plasma non-cholesterol
sterol and serum lipid concentrations ranged from one to
eight per variable. Because we excluded subjects with basalesisa Cholesterol absorptiona
High
(n Z 59)
Low
(n Z 59)
High
(nZ 59)
22/37 22/37 22/37
53.2  6.8 55.1  6.7 53.1  6.7
80.1  11.5 79.7  13.1 75.7  12.6
26.1  2.5 26.2  2.7 24.5  2.8
5.48  0.92 5.75  0.97 5.76  0.83
3.80  0.57 3.90  0.62 3.87  0.58
1.22  0.41 1.33  0.44 1.49  0.41
1.20 [0.86; 1.73] 1.22 [0.83; 1.74] 0.85 [0.71; 1.22]
4.46 [3.68; 6.36] 3.93 [3.35; 4.70] 9.37 [7.69; 11.07]
0.83 [0.67; 1.13] 0.70 [0.57; 0.82] 1.58 [1.44; 1.93]
] 7.85 [5.67; 10.39] 5.98 [5.19; 7.12] 16.15 [13.49; 19.77]
1.44 [1.06; 1.89] 1.07 [0.89; 1.23] 2.83 [2.42; 3.18]
0.60 [0.37; 0.95] 0.36 [0.24; 0.56] 1.17 [0.91; 1.54]
0.10 [0.07; 0.17] 0.06 [0.04; 0.09] 0.21 [0.16; 0.26]
0.39 [0.28; 0.60] 0.30 [0.22; 0.47] 0.39 [0.28; 0.56]
0.07 [0.04; 0.11] 0.05 [0.04; 0.09] 0.07 [0.05; 0.10]
8] 13.82 [10.43; 18.37] 10.62 [9.46; 12.86] 27.02 [22.26; 33.18]
2.55 [1.92; 3.23] 1.96 [1.66; 2.20] 4.70 [4.22; 5.41]
9.94 [8.38; 11.34] 8.39 [6.77; 10.91] 5.51 [4.37; 7.44]
1.80 [1.40; 2.07] 1.47 [1.22; 1.84] 1.00 [0.77; 1.24]
4.71 [3.79; 5.46] 4.75 [3.67; 5.62] 3.69 [2.83; 4.54]
0.81 [0.70; 0.97] 0.82 [0.67; 0.96] 0.66 [0.53; 0.81]
1.00 [0.74; 1.47] 0.85 [0.61; 1.19] 1.95 [1.62; 2.37]
0.18 [0.15; 0.25] 0.16 [0.11; 0.21] 0.35 [0.30; 0.41]
0.56 [0.38; 0.93] 0.46 [0.37; 0.85] 0.52 [0.41; 0.65]
0.09 [0.07; 0.15] 0.09 [0.06; 0.12] 0.09 [0.07; 0.12]
d data, as median [Q1; Q3].
ers were deﬁned using, as cut-offs, the gender-speciﬁc 25th and 75th
pesterol/TC ratio, respectively.
ulate the means or medians of the variables listed; per variable, a few
ol (TC) value from the same GC-MS assay.
Plasma plant sterols and cholesterol metabolism 305lathosterol/TC values (for the comparison betweenhigh and
low synthesizers) and sitosterol þ campesterol/TC values
(for the comparison between high and low absorbers) be-
tween the gender-speciﬁc 25th and 75th percentiles, only
half of the available datawereused to investigate the impact
of cholesterol metabolism. At the two intermediate blood
sampling visits (week 4 and 8), plasma non-cholesterol
sterols were only assessed in a subset of 100 subjects. Tak-
ing into account a few missing values, repeated plasma
sitosterol and campesterol concentrations were available
for 95 subjects to investigate the impact of intervention
duration.
By design, low synthesizers had lower lathosterol/TC
concentrations (median value: 0.84 mmol/mmol) vs. high
synthesizers (1.80 mmol/mmol) whereas low absorbers had
lower sitosterol þ campesterol/TC concentrations
(1.80 mmol/mmol) vs. high absorbers (4.37 mmol/mmol).
Compared to high cholesterol synthesizers, low synthe-
sizers had signiﬁcantly (P < 0.05) lower body weight, BMI,
triglycerides and desmosterol concentrations, and higher
total- and HDL-cholesterol, sitosterol, campesterol, bras-
sicasterol and sitostanol concentrations. Compared to high
cholesterol absorbers, low absorbers had signiﬁcantly
(P < 0.05) higher BMI, triglycerides, lathosterol and des-
mosterol concentrations, and lower HDL-cholesterol,
sitosterol, campesterol, brassicasterol, stigmasterol and
sitostanol concentrations. At baseline, the lathosterol/TC
ratio was signiﬁcantly, but modestly, inversely correlated
with the sitosterol þ campesterol/TC ratio (R Z 0.5;
P < 0.001).
Impact of intervention duration
During the 12-week intervention period, plasma sitosterol
and campesterol concentrations were unaltered in theFigure 1 Plasma sitosterol (A) and campesterol (B), serum total cholest
intervention with a low-fat spread with added plant sterols. The sitosterol a
had non-cholesterol sterol data at repeated time points. Results are express
and visit are shown based on the analyses with log-transformed data for pplacebo group. In the PS group, plasma sitosterol and
campesterol concentrations were 7.2 and 11.4 mmol/L at
baseline, respectively. Within the ﬁrst 4 weeks of inter-
vention, they increased by 69% (95%CI: 58; 82) and by 28%
(95%CI: 19; 39), respectively, but remained stable during
the following 8 weeks (P-valuetreatment*visit for
sitosterol Z 0.471 and P-valuetreatment*visit for
campesterol Z 0.950) (Fig. 1A and B).
The change from baseline in total- and LDL-cholesterol
was signiﬁcantly different at week 12 compared to weeks
4 and 8 (P-valuesvisit < 0.05; Fig. 1C and D). The largest
reductions in total- and LDL-cholesterol concentrations
were seen in the ﬁrst 4 weeks in the PS group
(0.36 mmol/L (95%CI: 0.49; 0.23) and 0.33 (95%CI:
0.43; 0.24), respectively). Concentrations stabilized
between week 4 and week 8 in both groups and were
further reduced in the PS group but also in the placebo
group between week 8 and week 12. In fact, LDL-
cholesterol was 0.19 mmol/L (95%CI: 0.05; 0.33) lower at
week 12 vs. week 8 in the placebo group and 0.14 mmol/L
(95%CI: 0.01; 0.27) lower in the PS group. Total cholesterol
was 0.30 mmol/L (95%CI: 0.11; 0.49) lower at week 12 vs.
week 8 in the placebo group and 0.23 mmol/L (95%CI:
0.05; 0.42) lower in the PS group. The interaction between
treatment*visit was not signiﬁcant (P-valuetreatment*visit for
total cholesterol Z 0.871 and P-valuetreatment*visit for LDL-
cholesterol Z 0.895), implying that the time curves of
total- and LDL-cholesterol were similar for individuals in
both groups.
Impact of cholesterol synthesis and absorption efﬁciency
PS intake signiﬁcantly increased concentrations of sitos-
terol, campesterol, brassicasterol and the sum of the four
major PS (with and without standardization for TC) in botherol (C) and LDL-cholesterol (D) concentrations during 12 weeks of
nd campesterol data are based on a subset of 95 subjects for which we
ed as means and 95%CI. P-values of the interaction between treatment
lasma sitosterol or campesterol.
Table 2 Changes in serum lipids and plasma non-cholesterol sterols in low and high cholesterol synthesizers after 12 weeks of plant sterol
intake.
Change from baseline vs. placebo P-value
All
(n Z 108b)
Low synthesizersa
(n Z 53)
High synthesizersa
(nZ 55)
Treatment Group Treatment  group
Total cholesterol, mmol/L 0.16 (0.43; 0.12) 0.12 (0.51; 0.28) 0.20 (0.58; 0.19) 0.259 0.639 0.780
LDL-cholesterol, mmol/L 0.19 (0.39; 0.01) 0.19 (0.47; 0.10) 0.20 (0.47; 0.08) 0.057 0.235 0.970
HDL-cholesterol, mmol/L 0.04 (0.04; 0.11) 0.08 (0.02; 0.19) 0.01 (0.11; 0.10) 0.304 0.957 0.242
Triglyceridesc, % 1.9 (8.8; 13.9) 2.1 (13.0; 19.8) 1.7 (12.9; 18.7) 0.738 0.514 0.973
Sitosterol, % 86.8 (65.8; 110.5) 70.1 (43.8; 101.4) 105.1 (73.7; 142.3) <0.001 0.296 0.118
Sitosterol/TCd, % 97.7 (74.8; 123.7) 79.9 (51.1; 114.1) 117.3 (83.0; 158.1) <0.001 0.379 0.125
Campesterol, % 36.7 (24.4; 50.2) 35.1 (18.3; 54.1) 38.3 (21.4; 57.7) <0.001 0.519 0.795
Campesterol/TC, % 43.5 (31.8; 56.4) 41.7 (25.7; 59.8) 45.4 (29.1; 63.7) <0.001 0.560 0.765
Brassicasterol, % 55.8 (27.0; 91.2) 47.3 (10.2; 96.9) 64.9 (24.2; 118.9) <0.001 0.699 0.579
Brassicasterol/TC, % 63.9 (33.4; 101.4) 54.0 (15.0; 106.3) 74.5 (31.3; 132.0) <0.001 0.708 0.541
Stigmasterol, % 20.6 (38.5; 2.6) 25.8 (48.9; 7.8) 15.0 (40.6; 21.5) 0.077 0.940 0.607
Stigmasterol/TC, % 15.8 (34.7; 8.7) 20.6 (45.2; 15.0) 10.6 (37.3; 27.5) 0.184 0.864 0.650
Plant sterolse, % 53.9 (38.6; 70.8) 45.5 (25.6; 68.5) 62.7 (40.9; 88.0) <0.001 0.868 0.276
Plant sterols/TC, % 62.4 (46.2; 80.4) 53.3 (32.3; 77.7) 72.1 (48.9; 98.8) <0.001 0.846 0.263
Lathosterol, % 10.9 (0.8; 22.1) 11.8 (2.6; 28.3) 10.1 (3.7; 25.9) 0.034 0.399 0.876
Lathosterol/TC, % 18.1 (7.9; 29.2) 19.6 (5.0; 36.2) 16.5 (2.7; 32.2) <0.001 0.721 0.779
Desmosterol, % 2.0 (6.7; 11.5) 1.6 (13.5; 11.8) 5.8 (6.6; 19.8) 0.656 0.434 0.422
Desmosterol/TC, % 8.3 (0.0; 17.2) 4.9 (6.5; 17.7) 11.7 (0.0; 24.9) 0.051 0.886 0.439
Sitostanol, % 5.5 (17.1; 7.8) 15.5 (29.9; 1.9) 5.7 (12.1; 27.1) 0.396 0.581 0.094
Sitostanol/TC, % 0.2 (12.1; 14.2) 10.4 (25.6; 7.9) 12.0 (6.8; 34.6) 0.980 0.656 0.093
Campestanol, % 9.2 (27.7; 14.2) 15.6 (39.2; 17.4) 2.3 (29.0; 34.5) 0.407 0.455 0.530
Campestanol/TC, % 3.8 (22.8; 19.9) 10.5 (34.8; 22.8) 3.5 (23.9; 40.7) 0.729 0.431 0.517
a High or low cholesterol synthesizers were deﬁned using the gender-speciﬁc 25th and 75th percentiles of the basal lathosterol/TC ratio as cut-
offs.
b This n is the maximal number of subjects that has been included to analyze the variables listed; per variable, a few missings may have been
present.
c In case of not normally distributed data (all non-cholesterol sterols and triglycerides), analysis was performed based on log transformed
values and results are expressed in % change from baseline vs. placebo.
d Non-cholesterol sterols were standardized by using the total cholesterol (TC) value from the same GC-MS assay.
e Plant sterols is the sum of sitosterol, campesterol, brassicasterol and stigmasterol.
306 R.T. Ras et al.high and low cholesterol synthesizers. Although increases
in most plasma PS seemed larger in the high synthesizers,
no signiﬁcant differences in treatment effects between
both groups were observed (P-valuestreatment*group > 0.05;
Table 2). When stratifying the individuals into high and
low cholesterol absorbers (Table 3), PS intake increased
concentrations of sitosterol, campesterol, brassicasterol
and the sum of the four major PS (with and without
standardization for TC). Again, the treatment*group
interactions were not signiﬁcant, except for the TC-
standardized change in the sum of the four major PS
(P-valuetreatment*groupZ 0.043) and a borderline signiﬁcant
effect for the change in TC-standardized sitosterol (P-
valuetreatment*groupZ 0.052), both showing larger increases
in low absorbers. The lathosterol/TC ratio increased
signiﬁcantly by 16e18% after PS intake vs. placebo,
reﬂecting an increased cholesterol synthesis rate with PS
intake.
Serum total- and LDL-cholesterol were reduced in
subgroups of low and high cholesterol synthesizers and
absorbers after PS intake by 0.16e0.20 mmol/L and
0.19 mmol/L, respectively, but these effects were not sta-
tistically signiﬁcant. In the total study population
(n Z 218), the reductions in total- and LDL-cholesterol
(0.26 and 0.26 mmol/L, respectively) were signiﬁcant as
reported previously [12]. No impact of baseline cholesterolsynthesis or absorption efﬁciency was observed on serum
lipid concentrations.
When exploring the placebo-corrected changes from
baseline in LDL-cholesterol and in the sum of plasma PS in
the various cholesterol synthesis and absorption groups
separately for men and women (Fig. 2), we observed
different effects in men and women when divided in
groups based on the synthesis marker lathosterol/TC ratio.
Men with a low lathosterol/TC ratio at baseline seemed to
have an enhanced LDL-cholesterol-lowering effect of PS
compared to men with high lathosterol/TC ratio. This
observation seemed reversed in women. Plasma PS in-
creases were not differently affected by cholesterol syn-
thesis and/or absorption markers in men and women,
except for a higher increase in plasma PS in men with low
vs. high sitosterol þ campesterol/TC ratio.Discussion
The current study shows that consumption of a low-fat
spread with added PS increases plasma concentrations of
sitosterol and campesterol (the two major PS in the
formulation) in the ﬁrst four weeks while no further in-
creases were observed in the following eight weeks. The
placebo-corrected reductions in serum total- and LDL-
Table 3 Changes in serum lipids and plasma non-cholesterol sterols in low and high cholesterol absorbers after 12 weeks of plant sterol intake.
Change from baseline vs. placebo P-value
All
(n Z 108b)
Low absorbersa
(nZ 54)
High absorbersa
(n Z 54)
Treatment Group Treatment  group
Total cholesterol, mmol/L 0.20 (0.50; 0.11) 0.18 (0.60; 0.25) 0.22 (0.66; 0.23) 0.209 0.466 0.903
LDL-cholesterol, mmol/L 0.19 (0.41; 0.02) 0.15 (0.45; 0.15) 0.23 (0.55; 0.08) 0.080 0.538 0.712
HDL-cholesterol, mmol/L 0.03 (0.06; 0.11) 0.01 (0.13; 0.11) 0.06 (0.07; 0.18) 0.567 0.965 0.490
Triglyceridesc, % 5.3 (17.0; 8.1) 5.0 (20.9; 14.1) 5.5 (21.9; 14.3) 0.419 0.840 0.964
Sitosterol, % 80.7 (59.3; 105.1) 100.3 (68.0; 138.7) 63.1 (35.9; 95.7) <0.001 0.561 0.111
Sitosterol/TCd, % 92.8 (68.5; 120.6) 120.3 (82.7; 165.6) 68.7 (38.9; 104.8) <0.001 0.905 0.052
Campesterol, % 29.6 (17.5; 43.1) 34.2 (17.0; 53.9) 25.3 (8.7; 44.3) <0.001 0.018 0.489
Campesterol/TC, % 37.9 (25.4; 51.5) 47.0 (29.0; 67.6) 29.3 (12.9; 48.0) <0.001 0.525 0.177
Brassicasterol, % 33.0 (7.6; 64.5) 34.8 (0.1; 81.6) 31.2 (3.3; 78.0) 0.009 0.003 0.899
Brassicasterol/TC, % 42.1 (14.8; 76.1) 49.7 (10.9; 102.0) 35.0 (0.7; 83.6) 0.002 0.007 0.635
Stigmasterol, % 21.5 (39.3; 1.5) 26.0 (48.0; 5.4) 16.8 (42.4; 20.2) 0.064 0.072 0.648
Stigmasterol/TC, % 16.4 (35.2; 7.8) 14.0 (40.2; 23.8) 18.8 (42.7; 15.2) 0.165 0.065 0.821
Plant sterolse, % 48.3 (32.7; 65.8) 60.8 (37.3; 88.3) 36.8 (16.9; 60.1) <0.001 0.285 0.152
Plant sterols/TC, % 58.5 (41.4; 77.6) 78.3 (51.7; 109.5) 40.8 (19.9; 65.5) <0.001 0.765 0.043
Lathosterol, % 9.0 (3.4; 22.9) 0.0 (15.2; 17.9) 18.7 (0.4; 41.5) 0.160 0.663 0.159
Lathosterol/TC, % 16.1 (3.8; 29.8) 9.3 (6.2; 27.4) 23.2 (4.6; 45.1) 0.010 0.893 0.292
Desmosterol, % 1.3 (8.2; 11.9) 6.8 (18.7; 6.9) 10.1 (4.7; 27.3) 0.795 0.099 0.100
Desmosterol/TC, % 7.7 (1.5; 17.9) 1.0 (10.8; 14.4) 15.0 (0.8; 31.1) 0.103 0.113 0.161
Sitostanol, % 9.3 (20.9; 4.0) 5.9 (22.2; 13.8) 12.6 (28.3; 6.4) 0.159 0.129 0.593
Sitostanol/TC, % 3.0 (15.6; 11.4) 3.9 (14.3; 25.9) 9.5 (25.9; 10.5) 0.660 0.306 0.327
Campestanol, % 18.0 (35.4; 4.0) 23.0 (44.4; 6.7) 12.8 (38.1; 23.0) 0.101 0.146 0.600
Campestanol/TC, % 12.8 (30.8; 9.7) 15.3 (38.1; 16.0) 10.3 (35.7; 25.0) 0.238 0.118 0.805
a High or low cholesterol absorbers were deﬁned using the gender-speciﬁc 25th and 75th percentiles of the basal sitosterol þ campesterol/TC
ratio as cut-offs.
b This n is the maximal number of subjects that has been included to analyze the variables listed; per variable, a few missings may have been
present.
c In case of not normally distributed data (all non-cholesterol sterols and triglycerides), analysis was performed based on log transformed
values and results are expressed in % change from baseline vs. placebo.
d Non-cholesterol sterols were standardized by using the total cholesterol (TC) value from the same GC-MS assay.
e Plant sterols is the sum of sitosterol, campesterol, brassicasterol and stigmasterol.
Plasma plant sterols and cholesterol metabolism 307cholesterol concentrations also occurred especially in the
ﬁrst four weeks of PS intake and remained stable thereafter.
The PS-induced changes in serum lipids and plasma non-
cholesterol sterolswere not different between high and low
cholesterol synthesizers (as deﬁned by the lathosterol/TC
ratio at baseline) or between high and low cholesterol ab-
sorbers (as deﬁned by the sitosterolþ campesterol/TC ratio
at baseline).
In the general population, campesterol concentrations
range from 6.9 to 27.9 mmol/L, whereas sitosterol levels
range from 2.8 to 16.0 mmol/L [9]. In our study, the con-
centrations at the end of the PS intervention increased up
to on average 16 mmol/L for campesterol and 13 mmol/L
for sitosterol, thus not exceeding physiological values.
Nevertheless, some concerns exist around elevated plasma
PS concentrations after PS-enriched food intake. Patients
with homozygous phytosterolemia have very high plasma
PS concentrations and often, but not always, experience
early onset of atherosclerosis [15]. Furthermore, some
observational studies suggested that moderately elevated
plasma PS concentrations may be associated with
increased CVD risk, but data is conﬂicting [16]. Although
concentrations of plasma PS seen in homozygous phytos-
terolemic patients [10] are 20e45 higher than the con-
centrations seen after PS-enriched food intake, and the
association between plasma PS and CVD risk may be
explained by plasma PS being a surrogate marker ofintestinal cholesterol absorption, investigation into the
impact of PS intake duration and cholesterol metabolism
efﬁciency was judged relevant.
Studies that investigate the cholesterol-lowering effect
of phytosterols often last for four weeks. This time period
is usually considered sufﬁcient for blood cholesterol con-
centrations to reach a new steady state after a dietary
intervention [17]. Indeed, our data show that, compared to
placebo, total- and LDL-cholesterol were lowered at week
4, and were not further reduced at weeks 8 and 12, as also
shown in other studies [18,19]. A surprising ﬁnding is,
however, that total- and LDL-cholesterol dropped by w5%
at week 12 vs. weeks 4 and 8 in both the placebo group
and in the intervention group. It explained the observed
12-week changes from baseline in the placebo group of
0.34 mmol/L and 0.22 mmol/L in total- and LDL-
cholesterol, respectively, that we reported previously
[12]. It could be that seasonal inﬂuences (i.e. the study
ended in summer) or increased awareness of having
elevated LDL-cholesterol have let to changes in the sub-
jects’ habits thereby unintendedly inﬂuencing their lipid
levels halfway the study.
Our study is the ﬁrst study that had repeated mea-
surements of plasma PS within a 12 weeks timeframe after
a daily intake of 3 g PS, which is the maximal intake
recommendation. We observed that plasma sitosterol and
campesterol concentrations were similar after 4 weeks
Figure 2 Explorative analysis showing placebo-corrected changes
from baseline in LDL-cholesterol (A) and in the sum of the four major
plasma plant sterols (sitosterol, campesterol, brassicasterol and stig-
masterol; B) for groups of low and high cholesterol synthesis (deﬁned
by the baseline lathosterol/TC ratio) and absorption (deﬁned by the
baseline sitosterol þ campesterol/TC ratio), separately for women and
men. Results are expressed as Least squares means and 95%CI.
308 R.T. Ras et al.and after 8 and 12 weeks of intervention, conﬁrming
previously reported data for low doses of PS (<0.5 g/d)
[20,21]. Longer-term intervention studies (up to 85 weeks)
have also shown that plasma PS do not further increase
with sustained PS intake [22,23].
The relationship between cholesterol synthesis and
cholesterol absorption is suggested to be reciprocal [24];
high synthesizers are usually low absorbers whereas low
synthesizers are usually high absorbers. Indeed, our anal-
ysis of the baseline data showed that those individuals
with high lathosterol/TC ratios had signiﬁcantly lower TC-
standardized plasma PS concentrations compared to those
with low lathosterol/TC ratios. On the contrary, individuals
with high vs. low sitosterol þ campesterol/TC ratios had
lower TC-standardized lathosterol concentrations at
baseline. High synthesizers and low absorbers also had
higher body weight, BMI, triglycerides, and lower HDL-
cholesterol, thus reﬂecting to some extent a metabolic
syndrome population.
Based on earlier ﬁndings, we hypothesized that low
cholesterol synthesis [11,25,26] and high cholesterol ab-
sorption [26e29] would be associated with a larger
cholesterol-lowering effect of PS intake. We were not able
to conﬁrm such a potential inﬂuence of cholesterol
metabolism efﬁciency on cholesterol-lowering efﬁcacy.
Based on explorative analysis (Fig. 2), there was however
some indication that a larger cholesterol-lowering efﬁcacy
with PS intake in low vs. high synthesizers, as e.g.
observed in the study by MacKay et al. [11], may only been
seen in men and not in women. Further research is neededto investigate this potential interaction between treat-
ment, cholesterol synthesis rate and sex.
Whether cholesterol synthesis and/or absorption efﬁ-
ciency would also explain some of the variation in in-
creases in plasma PS after PS-enriched food intake has not
frequently been studied. One could hypothesize that in-
dividuals with high cholesterol absorption efﬁciency may
hyperabsorb PS and show large elevations in plasma con-
centrations upon PS intake. On the other hand, in in-
dividuals with low baseline plasma PS, there may be more
room for plasma PS to increase after PS intake. Houwe-
lingen et al. [14] found that plasma campesterol concen-
trations were more increased in individuals with low vs.
high plasma PS at baseline, but this treatment by group
interaction was not statistically signiﬁcant. We observed
larger increases in plasma sitosterol and in the sum of the
four major PS (sitosterol, campesterol, brassicaterol and
stigmasterol) in subjects with low vs. high plasma
sitosterol þ campesterol/TC at baseline, but also without a
signiﬁcant treatment by group interaction. Only the TC-
standardized increases in sitosterol and the sum of the
four major PS were borderline signiﬁcantly different be-
tween low and high absorbers, but this effect is likely
inﬂated by the expected reduction in total cholesterol with
PS intake. Nevertheless, our data do not provide any
indication that PS are potentially hyperabsorbed by those
with high basal cholesterol absorption rates.
Our study has several limitations that deserve
mentioning. First, our study was not speciﬁcally designed
to investigate the impact of cholesterol metabolism efﬁ-
ciency on the cholesterol-lowering effect of PS like the
study by MacKay et al. [11]. This study prospectively
selected subjects with high or low TC-standardized lath-
osterol concentrations. To be able to compare our ﬁndings
with those of MacKay et al., we applied similar exclusion
criteria to select our study population. Second, our study
was designed as a parallel study and not as a crossover
study. The subjects could therefore not serve as their own
control. As a compromise, we adjusted our analysis for the
concentrations at baseline.
In conclusion, increases in plasma PS and reductions in
total- and LDL-cholesterol concentrations clearly stabilized
within the ﬁrst four weeks of PS intervention. The in-
creases in plasma PS were not signiﬁcantly impacted by
basal cholesterol synthesis or absorption efﬁciency.
Furthermore, we could not conﬁrm an enhanced
cholesterol-lowering effect of PS intake in low vs. high
cholesterol synthesizers or in high vs. low cholesterol ab-
sorbers as observed in some other studies. More studies,
speciﬁcally designed to investigate this matter, are needed
to be able to elucidate sources of heterogeneity in
responsiveness to PS treatment.
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